No Data
No Data
Biomea Fusion Advances Diabetes Treatment With Positive Study Results
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
12 Health Care Stocks Moving In Tuesday's Pre-Market Session